Available Sessions:

March 24, 2010 12:45 PM ET

Sponsors:

This program is jointly sponsored by the University of Michigan Medical School and IMPACt, Inc.

Commercial Support:

This activity is supported by educational grants from Pfizer and AstraZeneca.

Description:

This activity will discuss current strategies as well as promising future directions in overcoming endocrine therapy resistance in breast cancer.  Presentations will include an overview of the molecular pathways and potential therapies under investigation.

Learning Objectives:

Upon completion of this activity, participants will be able to:

1. Describe current strategies to overcome endocrine therapy resistance
2. Describe molecular pathways being investigated that may play a role in endocrine therapy resistance
3. Describe recent and on-going research into potential therapies to overcome endocrine therapy resistance

Target Audience:

This activity has been designed to meet the educational needs of medical oncologists involved in the care of patients with breast cancer.
 

Accreditation Statement:

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the University of Michigan Medical School and IMPACT, Inc. The University of Michigan Medical School is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation:

The University of Michigan Medical School designates this activity for a maximum of 1 AMA PRA Category 1 Ccredit^TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Agenda:

Topics to be discussed include:

1. Basic/translational aspects of hormone-resistance, introduce role of growth factors in hormone-resistance, mTOR, IGF1R
2. High dose estrogen, VEGF inhibitors in hormone-resistance
3. Role of HER2/EGFR in intrinsic and acquired resistance, review trials on trastuzumab, lapatinib and EGFR inhibitors in reversing hormone resistance
4. Putting it all together: HER2-positive metastatic case history

1. Discussion/Q&A

Faculty:

Ruth O'Regan, MD (Course Director)
Associate Professor of Hematology and Medical Oncology
Chief of Hematology and Medical Oncology
Georgia Cancer Center for Excellence at Grady Memorial Hospital
Louisa and Rand Glenn Family Chair in Breast Cancer Research
Director Hematology Oncology Fellowship Program
Director Translational Breast Cancer Research Program
Medical Director, Emory Breast Center
Emory University School of Medicine
Winship Cancer Institute

Claudine Isaacs, MD
Associate Professor of Medicine and Oncology
Director, Clinical Breast Cancer Program
Lombardi Comprehensive Cancer Center

Maura N. Dickler, MD
Assistant Attending Physician, Breast Cancer Medicine Service
Solid Tumor Division, Department of Medicine
Memorial Sloan-Kettering Cancer Center

University of Michigan CME Content Reviewer
Samuel M. Silver, MD
Professor and Associate Dean for Research
University of Michigan Medical School
Director, University of Michigan Cancer Center Network
University of Michigan Healthcare Network

Disclosure of Conflicts of Interest:

The University of Michigan Medical School endorses the Standards of the Accreditation Council for Continuing Medical Education and the Guidelines of the Association of American Medical Colleges that the sponsors of continuing medical education activities and the speakers at these activities disclose significant relationships with commercial companies whose products are discussed in educational presentations.  Disclosure of a relationship is not intended to suggest or condone bias in any presentation, but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

Significant relationships exist with the following companies whose products will be discussed.

Ruth O’Regan, MD
Grant/Research:      Genentech/Roche and Pfizer

Maura N. Dickler, MD
Consultant:  Genentech/Roche, Novartis, AstraZeneca,  Pfizer    and    GlaxoSmithKline
Grant/Research:  Genentech/Roche and Abraxis

Claudine Isaacs, MD
Speaker’s  Bureau:  GlaxoSmithKline, Abraxis, Genentech, Novartis     and AstraZeneca

 Samuel M. Silver, MD, PhD
 Consultant:  Blue Cross Blue Shield of Michigan
 Grant/Research:  Blue Cross Blue Shield of Michigan